Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 240 participants.
Also called NCT07389941
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 240 participants
- Sponsor
- Registry
-
NCT07389941
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07389941. Randomized; single masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2029-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation
- Acronym
- SPICE-AF
- Condition
- Atrial Fibrillation (AF)
- Intervention (Drug)
- Semaglutide (SEMA)
- Lead sponsor
- University of Luebeck
Record details
- Record id
cardio:ct-nct07389941- Content hash
9a46e3e643eb2e471c8598880dd3d5d7b2e2a9615baf378deb9603061a6dad9e